doi: 10.1016/0169-6009(90)90040-m.
Hypoparathyroidism: practice and theoretical backgrounds for 1 alpha(OH)D3 treatment
Affiliations
- PMID: 2364181
- DOI: 10.1016/0169-6009(90)90040-m
Item in Clipboard
Hypoparathyroidism: practice and theoretical backgrounds for 1 alpha(OH)D3 treatment
Bone Miner.
1990 Jun.
No abstract available
Similar articles
-
Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.Nephron. 1989;53(3):194-200. doi: 10.1159/000185744. Nephron. 1989. PMID: 2797340
-
[Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].Pol Arch Med Wewn. 1993 Feb;89(2):95-101. Pol Arch Med Wewn. 1993. PMID: 8502602 Polish.
-
Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.Ren Fail. 1994 Nov;16(6):715-23. doi: 10.3109/08860229409044901. Ren Fail. 1994. PMID: 7899583 Clinical Trial.
-
Hormonal control of skeletal and mineral homeostasis.Am J Med. 1974 Jun;56(6):751-8. doi: 10.1016/0002-9343(74)90802-x. Am J Med. 1974. PMID: 4364694 Review. No abstract available.
-
1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.Nephron. 1995;71(3):254-83. doi: 10.1159/000188732. Nephron. 1995. PMID: 8569975 Review.
Cited by
-
Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.Rheumatol Int. 2007 Dec;28(2):103-11. doi: 10.1007/s00296-007-0422-6. Epub 2007 Aug 1. Rheumatol Int. 2007. PMID: 17668216 Review.
-
Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol.Rheumatol Int. 2004 Jul;24(4):189-97. doi: 10.1007/s00296-004-0454-0. Epub 2004 Jun 30. Rheumatol Int. 2004. PMID: 15232715 Review.